Description

CJC-1295 / Ipamorelin Blend 20 mg — Dual GH-Stimulating Peptide Combination for Endocrine Research

The CJC-1295 / Ipamorelin Blend combines two complementary peptides in a single vial to support paired research into pulsatile growth hormone (GH) release. CJC-1295 is a synthetic GHRH analog that extends GHRH receptor signaling, while Ipamorelin is a selective growth hormone secretagogue receptor (GHS-R / ghrelin receptor) agonist. Together, this blend has been studied for its synergistic effects on GH pulse amplitude, IGF-1 levels, and body composition markers in research models.

What It Is

• Class: Combined GHRH analog (CJC-1295) + selective ghrelin receptor agonist (Ipamorelin)
• Concept: Two complementary mechanisms in one vial — CJC-1295 extends GHRH-receptor signaling for sustained baseline activity, while Ipamorelin drives pulsatile GH release via a separate ghrelin-receptor pathway.
• Format: Research-grade synthetic peptide blend supplied as a lyophilized powder.

Proposed Mechanisms (Preclinical)

Dual-Pathway GH Stimulation

• CJC-1295 activates GHRH receptors on pituitary somatotrophs, supporting elevated baseline GH secretion.
• Ipamorelin selectively binds the GHS-R / ghrelin receptor, triggering pulsatile GH release without significant cortisol or prolactin elevation in research models.
• Combined activation has been investigated for amplified GH pulse responses compared to either compound alone.

Downstream Endocrine Effects

• Research explores changes in IGF-1 levels, GH pulse amplitude, and frequency patterns.
• Investigations into lean mass, body composition indices, and recovery markers.
• Studies of sleep architecture and circadian GH release patterns.
• Examination of selective specificity — Ipamorelin’s profile of minimal cross-activation of cortisol, prolactin, or aldosterone pathways.

Selected Research Highlights

• Synergistic GH Release: Research has compared blend responses to single-compound administration, with reported amplified pulse amplitudes when both pathways are engaged simultaneously.
• Selectivity Studies: Investigations of Ipamorelin’s selective profile, particularly its lack of significant impact on non-GH endocrine axes.
• Body Composition Research: Animal studies examining changes in lean mass, adipose tissue, and recovery markers with combined GHRH/ghrelin pathway stimulation.
• Sustained-Release Pharmacology: CJC-1295’s extended half-life relative to native GHRH has been characterized in pharmacokinetic studies.

Chemical & Handling Information

• Type: Combined synthetic peptide blend
• Components: CJC-1295 (GHRH 1–29 analog, modified for stability) and Ipamorelin (5-amino-acid pentapeptide selective for GHS-R) — exact ratio and individual amounts per lot specification
• Appearance: White to off-white lyophilized powder
• Solubility: Reconstitutes readily in bacteriostatic water or sterile saline for laboratory preparation

Specifications

• Peptide Blend: CJC-1295 + Ipamorelin
• Amount: 10 mg total per vial
• Form: Lyophilized powder
• Purity: ≥99% (HPLC); COA per lot available
• Packaging: Sealed glass vials with rubber stopper and aluminum crimp seal, suitable for standard laboratory handling

Storage & Stability

• Store lyophilized vials in a cool, dry place, protected from light.
• Refrigeration or freezing of the lyophilized peptide is recommended for extended stability, in accordance with standard laboratory SOPs.
• After reconstitution, store at 2–8 °C for short-term laboratory use (typically up to 30 days).
• For long-term storage of reconstituted material, aliquot and freeze at −20 °C or below.
• Avoid repeated freeze-thaw cycles, which can degrade peptide integrity.

Research Use Disclaimer

This product is sold strictly for laboratory research use only. Not intended for human or animal consumption. Not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease or condition. Customers are solely responsible for the lawful handling, storage, and use of this product in accordance with all applicable laws and regulations.